AstraZeneca Advances to Phase III with PD-1xTIGIT BsAb for Biliary Tract Cancer
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, is set to initiate a Phase III...
Multi-specific antibodies
Biocytogen Pharmaceuticals Inks Antibody Deal with Neurocrine Biosciences
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd, (HKG: 2315) has announced an antibody assessment and option...
AbbVie and Genmab’s Epcoritamab Shows Promising Results in Follicular Lymphoma Study
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have presented Phase I/II clinical data for their...
Amgen’s Tarlatamab Receives FDA Priority Review for Advanced Small Cell Lung Cancer Treatment
The US Food and Drug Administration (FDA) has granted priority review status to Amgen (NASDAQ:...
BMS Advances TIGITxCD96 Bispecific Antibody into Phase II Dose Expansion
Bristol Myers Squibb (BMS; NYSE: BMY) has advanced its development program for the TIGITxCD96 bispecific...
Roche’s Mosunetuzumab and AnHeart’s Taletrectinib Poised for Priority Review in China
The China Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Lunsumio...
AbbVie’s Epcoritamab Earns EMA Review and FDA Breakthrough Designation for Follicular Lymphoma
AbbVie’s (NYSE: ABBV) bispecific antibody (BsAb) Tepkinly/Epkinly (epcoritamab) has been accepted for review by the...
RemeGen’s Telitacicept Receives Full Approval for Systemic Lupus Erythematosus in China
China-based pharmaceutical company RemeGen (HKG: 9995) has announced the conversion of conditional approval to complete...
Janssen Submits Indication Extension Application to FDA for Rybrevant in NSCLC Treatment
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has filed an indication extension...
Roche’s Lymphoma Therapy Columvi Receives NMPA Approval for Adult Patients with Relapsed DLBCL
Swiss pharmaceutical giant Roche (SWX: ROG) has announced that it has received market approval from...
BioNTech Secures Exclusive Rights to Biotheus Inc.’s BsAb PM8002 in Landmark Deal
Germany’s BioNTech (NASDAQ: BNTX) has entered into an exclusive license and collaboration agreement with China-based...
BeiGene’s ZW25 on Track for Priority Review for Cholangiocarcinoma Treatment by CDE
The Center for Drug Evaluation (CDE) website has indicated that BeiGene’s (NASDAQ: BGNE) ZW25 (zanidatamab)...
Pfizer Inc. Reports Q3 2023 Revenue Contraction and Launches Cost Realignment Program
US pharmaceutical giant Pfizer Inc., (NYSE: PFE) has released its financial results for the third...
Amgen Reports Q3 2023 Financials: 5% Growth Driven by Volume Expansion
Amgen (NASDAQ: AMGN) has released its Q3 2023 financial results, showcasing a 5% year-on-year (YOY)...
Roche’s Vabysmo Receives FDA Approval for Macular Edema Treatment Following RVO
Swiss pharmaceutical giant Roche (SWX: ROG) announced last week that it has received an indication...
TG ImmunoPharma’s Bispecific Antibody TGI-6 Approved for Phase I Clinical Study by NMPA
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the National...
CSPC Pharmaceutical Gains NMPA Approval for Clinical Study of Bispecific Antibody NBL-028
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Roche Agrees to Acquire Telavant for $7.1 Billion to Boost IBD Treatment Portfolio
Switzerland-headquartered pharmaceutical giant Roche (SWX: ROG) announced this week an agreement to purchase Telavant Holdings,...
Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023
China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...
Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023
China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...